Analysts forecast that Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) will announce earnings per share (EPS) of ($0.54) for the current quarter, according to Zacks. Zero analysts have issued estimates for Verrica Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.49). Verrica Pharmaceuticals reported earnings of $0.02 per share during the same quarter last year, which would indicate a negative year over year growth rate of 2,800%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Verrica Pharmaceuticals will report full year earnings of ($2.27) per share for the current financial year, with EPS estimates ranging from ($2.48) to ($2.00). For the next financial year, analysts expect that the company will report earnings of ($1.70) per share, with EPS estimates ranging from ($2.26) to ($1.26). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Verrica Pharmaceuticals.
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) last issued its earnings results on Wednesday, March 2nd. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.13.
NASDAQ VRCA traded down $0.15 on Monday, hitting $6.42. 6,921 shares of the company were exchanged, compared to its average volume of 67,032. The stock has a market capitalization of $176.67 million, a P/E ratio of -4.98 and a beta of 1.97. Verrica Pharmaceuticals has a 12 month low of $6.40 and a 12 month high of $14.79. The stock’s fifty day moving average is $8.01.
Institutional investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA grew its position in shares of Verrica Pharmaceuticals by 307.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 2,579 shares of the company’s stock worth $32,000 after buying an additional 1,946 shares during the period. Citigroup Inc. lifted its stake in Verrica Pharmaceuticals by 163.1% during the 4th quarter. Citigroup Inc. now owns 4,296 shares of the company’s stock valued at $39,000 after acquiring an additional 2,663 shares during the period. Allspring Global Investments Holdings LLC bought a new position in Verrica Pharmaceuticals during the 4th quarter valued at about $52,000. Barclays PLC lifted its stake in shares of Verrica Pharmaceuticals by 213.5% in the 3rd quarter. Barclays PLC now owns 5,352 shares of the company’s stock worth $67,000 after purchasing an additional 3,645 shares during the period. Finally, Truist Financial Corp bought a new position in shares of Verrica Pharmaceuticals in the 1st quarter worth approximately $92,000. 34.58% of the stock is currently owned by institutional investors and hedge funds.
Verrica Pharmaceuticals Company Profile (Get Rating)
Verrica Pharmaceuticals Inc, a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.
- Get a free copy of the StockNews.com research report on Verrica Pharmaceuticals (VRCA)
- onsemi Is A Deep-Value In The Chip Sector
- Is The FOMC About To Spark A Massive Stock Market Correction?
- Knight-Swift Transportation Stock is a Logistics Winner
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Why is Chevron Stock Falling After Strong Earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.